BioSpace News Archive

VolitionRx Limited has announced the launch of its Nu.Q® Vet Cancer Test in Asia through its appointed distributor SAGE Healthcare Private Limited.

Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that its partner, Wanbang Biopharmaceuticals enrolled the final patient, ahead of schedule, in its pivotal Phase 3 clinical trial for Triferic® (ferric pyrophosphate citrate) Dialysate to support a new drug application for regulatory approval in China.

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), today announced the publication of data demonstrating that treatment with avexitide significantly reduced the likelihood of fasting and protein-induced hypoglycemia in patients with congenital hyperinsulinism (HI).

Xbiome expects to commence Phase 1b trial of next-generation oral live biotherapeutic product program M201 in 2022.

Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo.

PolyPid Ltd. announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022.

Actinium Pharmaceuticals, Inc. today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of Iomab-B.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022.

Gossamer Bio, Inc. today announced topline results from its Phase 2 SHIFT-UC Study clinical trial studying GB004 in patients with mild-to-moderate active ulcerative colitis (UC).

Catalyst Pharmaceuticals, Inc. announced that it will release its first-quarter 2022 financial results after market close on Tuesday, May 10, 2022.